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PTEN and PIK3CA Expression Is Associated with Prolonged
Survival after Gefitinib Treatment in EGFR-Mutated Lung
Cancer Patients
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Hiroyuki Kuwano, MD, PhD,‡ and Tetsuya Mitsudomi, MD, PhD*
Background: We and other researchers have previously reported
that pulmonary adenocarcinomas with epidermal growth factor re-
ceptor (EGFR) mutations are usually sensitive to geﬁtinib, an
EGFR-speciﬁc tyrosine kinase inhibitor, although this relationship is
not complete. In this study, we searched for mutations or changes in
the expression of genes downstream to EGFR and evaluated their
relationship with the effectiveness of geﬁtinib.
Methods: We studied 78 lung cancer patients who had recurrent
disease after surgical resection and were treated with geﬁtinib. We
searched for mutations occurring in the KRAS and PIK3CA gene.
We also evaluated the expression level of EGFR, PIK3CA, and
PTEN by real-time reverse transcriptase polymerase chain reaction.
Geﬁtinib effectiveness was evaluated by imaging studies; a survival
analysis was also done.
Results: We found seven (9%) somatic mutations in KRAS and two
(2%) in PIK3CA. EGFR mutations were present in 44 (56%). KRAS
mutations were found only in tumors without EGFR mutations,
whereas PIK3CA mutation was found in tumors with EGFR muta-
tion. Tumor response was assessable in 52 tumors. None of the six
tumors with KRAS mutations responded to geﬁtinib treatment;
however, two tumors with PIK3CA mutations showed partial response.
Survival was signiﬁcantly longer in patients with EGFR mutations or in
those without KRAS mutations. In tumors with EGFR mutations,
survival was longer in those with high PIK3CA or PTEN expression
than in those with low expression of these molecules.
Conclusions: An evaluation of the KRAS mutation, as well as
PIK3CA and PTEN expression, might help identify lung cancer
patients who are most suitable for geﬁtinib treatment.
Key Words: Non-small cell lung carcinomas, Epidermal growth
factor receptor, Geﬁtinib, Phosphatidylinositol 3=-kinase catalytic
alpha, PTEN.
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Geﬁtinib (Iressa) is an orally bioavailable tyrosine kinaseinhibitor (TKI) speciﬁc for epidermal growth factor
receptor (EGFR). Recently, we, as well as others, have
reported that activating mutations of EGFR are present in a
subset of pulmonary adenocarcinomas and that tumors with
EGFR mutations are highly sensitive to geﬁtinib.1–7 How-
ever, about 10% of patients who exhibited a clear beneﬁt
from geﬁtinib treatment did not have an EGFR mutation, and
about 20% of patients with an EGFR mutation did not
respond to the geﬁtinib treatment 1–7.
After ligand binding, EGFR is autophosphorylated at
several tyrosine residues. This autophosphorylation then
turns on downstream signaling pathways, including the Ras/
Raf/mitogen-activated protein kinase (MAPK) pathway and
the phosphatidyl inositol 3=-kinase (PI3K)-Akt pathway. The
MAPKs have been linked to cell proliferation and transfor-
mation in vitro.8 The Akt pathway plays a critical role in
facilitating cell survival.9 Phosphatidylinositol 3=-kinase cat-
alytic alpha (PIK3CA) positively regulates Akt, whereas
PTEN negatively regulates Akt. Recently, PIK3CA has been
reported to have somatic mutations in some colorectal, gas-
tric, and lung cancers.10 If alteration of PIK3CA or PTEN
functionally activates Akt, then it is possible that these
tumors would have a different response to geﬁtinib treatment.
Indeed, expression of phosphorylated-Akt (p-Akt) has been
reported to be predictive of response to geﬁtinib.6,11
In this study, we added 19 more patients to the 59
patients previously analyzed for EGFR mutations,5 searched
for mutations in the KRAS and PIK3CA genes, and quanti-
tated messages of EGFR, PIK3CA, and PTEN by reverse
transcriptase polymerase chain reaction (RT-PCR) in an at-
tempt to conﬁrm and extend our previous ﬁndings.5
PATIENTS AND METHODS
Patients and Gefitinib Treatment
From July 2002 through November 2004, 79 patients
were treated with geﬁtinib for more than 3 weeks for recur-
rent disease after they had undergone pulmonary resection
between 1997 and 2004. We studied 78 patients whose
tumors were available for RNA extraction. There were 44
men and 34 women with a median age at operation of 61.9
(range, 39–80) years, and a median age at starting oral
geﬁtinib treatment of 64.3 (range, 40–85) years. Forty-ﬁve
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patients were former/current smokers, with a median pack-
years (number of cigarette packs per day times years) of 40;
the remaining 33 were never smokers. Sixty-eight patients
had adenocarcinomas, six had squamous cell carcinomas,
three had large cell carcinomas, and one had adenosquamous
carcinoma. Twelve patients had stage IA disease, nine had
stage IB, three had stage IIA, seven had stage IIB, 32 had
stage IIIA, 10 had stage IIIB, and ﬁve had stage IV at the time
of surgery. Forty-nine patients had received chemotherapy
before geﬁtinib treatment (29, platinum doublet; 18, vinorel-
bine or gemcitabine monotherapy; two, oral uracil-tegafur
[UFT]). Twenty patients did not receive any chemotherapy or
radiotherapy before geﬁtinib treatment. Geﬁtinib 250 mg/day
was started, and the patients were followed until February
2005, with a median duration of 121 (range, 23–939) days. In
61 patients, oral geﬁtinib was stopped due to progressive
disease in 30, no change in four, regrowth after partial
response in 16, and adverse reactions in 11. Response to
geﬁtinib treatment was judged according to RECIST, except
that conﬁrmation at 4-week intervals was not necessarily
mandated. Measurable disease was present in 52 of 78 tu-
mors, and tumor response was evaluated in these subjects.
Mutation Analysis of Lung Cancer Specimens
After obtaining appropriate approval from the institu-
tional review board and written informed consent from the
patients, tumor samples were rapidly frozen in liquid nitrogen
and stored at 80°C after resection. A surgical pathologist
(Y.Y.) grossly dissected the frozen tumor specimens to enrich
the tumor cell population as much as possible. Total RNA
was isolated using the RNeasy kit (Qiagen, Valencia, CA).
After cDNA was converted, an EGFR mutation at tyrosine
kinase (exon 18-21) and a KRAS mutation at codons 12, 13,
and 61 were searched for as described previously.12 RT-PCR
products were diluted and directly sequenced using the Big
Dye Terminator v3.1/1.1 cycle sequencing kit (Applied Bio-
systems, Foster City, CA) according to the manufacturer’s
instructions. Sequencing products were electrophoresed on an
ABI PRISM 3100 (Applied Biosystems). Both the forward
and reverse sequences obtained were analyzed by BLAST,
and chromatograms were manually reviewed.
Mutations of PIK3CA occurring in a whole open read-
ing frame were searched. Primer sequences were designed
according to GenBank (accession number NM 006218); these
are available upon request. The RT-PCR conditions were one
cycle of 95°C for 11 minutes, 45 cycles of 95°C for 35
seconds, 62°C for 35 seconds, 72°C for 55 seconds, followed
by one cycle of 72°C for 10 minutes.
Expression Analysis of Lung Cancer Specimens
Expression of EGFR, PIK3CA, and PTEN genes was
quantitated using the SYBR Green method (QuantiTect
SYBR Green PCR Kit; Qiagen) on ABI7900HT (Applied
Biosystems). Primer sequences are available upon request.
Quantitation was performed in duplicate, and the expression
level of 18S ribosomal RNA (rRNA) was used as an internal
control. Expression values of each gene were used as relative
values compared with control sample (RERF-LC-AI, adeno-
carcinoma cell line).
Statistical Analysis
To compare proportions, the 2, t, or Kruskal-Wallis
test was used. The Kaplan-Meier method was used to esti-
mate the probability of survival as a function of time, and
survival differences were analyzed by the log-rank test. The
two-sided signiﬁcance level was set at p  0.05. The Cox
proportional hazards modeling technique was applied for
univariate or multivariate analysis of the overall survival. All
analyses were performed using StatView (Version 5, SAS
Institute Inc., Cary, NC) software.
RESULTS
Mutations of KRAS, PIK3CA, and EGFR Gene
KRAS mutations at codon 12 (three G12C and one
G12A, G12D, G12S, and G12V each) were found in seven
patients. PIK3CA mutations occurring at codon 545 (E545K)
in exon 9 were found in two patients (2.5%). These two
patients were females who had never smoked and who had
adenocarcinomas harboring an EGFR mutation (L858R). Of
78 patients, EGFR mutations were found in 44 (56%): two
point mutations in exon 18 (G719A, G719C), 23 deletions in
exon 19, two insertions in exon 19 (I744KIPVAI), one point
mutation in exon 20 (S768I), and 16 point mutations in exon
21 (15 L858R, one L861Q). In three patients, there was a
second mutation (L858R  A871G, L858R  E709G,
G719C  E709H). Of the 44 patients with EGFR mutations,
23 were female, 23 were never smokers, and 43 had an
adenocarcinoma. As reported previously, EGFR mutations
and KRAS mutations were mutually exclusive.12
Expression Analysis of EGFR, PIK3CA, and PTEN
Gene
Real-time RT-PCR analyses were performed for the
EGFR, PIK3CA, and PTEN genes. Quantitation was per-
formed in duplicate, and correlations between these two
assays were high (R 2 were 0.89 for rRNA, 0.95 for EGFR,
0.92 for PIK3CA, and 0.89 for PTEN; Pearson’s test). EGFR
expression was signiﬁcantly higher in tumors with EGFR
mutations than in those without EGFR mutations; the relative
value of the mutation group was 1.876 times that of the wild
types (p  0.0075; t test). However, the expressions of
PIK3CA and PTEN were not associated with EGFR mutation;
the expression ratio of PIK3CA between EGFR mutations and
the wild types was 0.889 (p  0.5911), whereas the expres-
sion ratio of PTEN between EGFR mutations and the wild
types was 0.954 (p  0.8481).
Relationship between Response and Mutations
Of 52 patients with measurable disease, 24 showed
partial response (PR), 19 showed progressive disease (PD),
and the remaining nine patients exhibited stable disease (SD).
Of the 27 patients with EGFR mutation, 22 (81%) patients
showed PR, three SD, and two PD. However, in the 25
patients without EGFR mutations, only two patients (8%)
showed PR, six SD, and 17 PD (Table 1). In contrast, none of
six tumors with KRAS mutations responded to geﬁtinib treat-
ment (Table 1).
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There were only two patients with a PIK3CA mutation,
and they also had an EGFR mutation (L858R). These two
patients showed PR. Due to a limited number of PIK3CA
mutations, it was difﬁcult to evaluate the isolated effect of a
PIK3CA mutation on tumor response.
Relationship between Response and
Expressions
When the patients were divided into two groups ac-
cording to the median value of gene expression, tumors with
high EGFR expression were signiﬁcantly more responsive to
geﬁtinib than those with low EGFR expression (18 cases of
26 high expressions showed PR, and 13 cases of 26 low
expressions showed PD, p 0.0034; 2 test) (Table 1). When
we compared to the groups as mean expression value of
EGFR, expression in PR group was signiﬁcantly higher than
that in SD or PD groups (Table 2). On the other hand,
expression of PIK3CA or PTEN did not affect the response
rate.
Effect of Molecular Alterations on Patient
Survival after Gefitinib Treatment
Patients with KRAS mutations survived for a signiﬁ-
cantly shorter time from the day of starting geﬁtinib than
those without KRAS mutations (p  0.0323, Fig. 1B). We
also conﬁrmed the favorable effect of EGFR mutations on
patient survival as reported previously (p  0.0040; log-rank
test, Fig. 1A).
On the other hand, while EGFR expression did not
appear to affect survival time (Fig. 2A), high expressions of
PIK3CA and PTEN were associated with prolonged survival
(Fig. 2B and C). Of interest, when effects of EGFR mutations
with or without high expression of PIK3CA or PTEN were
simultaneously analyzed, only patients in the group with
EGFR mutations and high expression of PIK3CA or PTEN
showed longer survival (PIK3CA: p  0.0071, PTEN: p 
0.0614; log-rank test; Fig. 3A and B).
Because a cutoff line of gene expression is hard to
determine, univariate analyses of sequential expression data
were also performed to assess the correlations among expres-
sions and clinical outcome. High expression of each gene was
associated with prolonged survival; hazard ratio (HR) of
EGFR was 0.797 (p  0.1115), HR of PIK3CA was 0.367
(p  0.0946), and HR of PTEN was 0.108 (p  0.0685)
(Table 3). However, Cox’s proportional hazards model failed
to show an independent contribution of these variables to
overall survival (data not shown).
TABLE 1. Relationship between Gene Mutation/Expression
and Gefitinib Effectiveness
Imaging evaluation
Gene Category Total PR SD PD pa
EGFR Wild type 25 2 6 17 0.0001
Mutation 27 22 3 2
EGFR mutation L858R 8 6 1 1 0.3261
Deletion 17 15 2 0
KRAS Wild type 46 24 8 14 0.0274
Mutation 6 0 1 5
PIK3CA Wild type 50 22 9 19 0.2972
Mutation 2 2 0 0
EGFR High expression 26 18 2 6 0.0034
Low expression 26 6 7 13
PIK3CA High expression 26 13 4 9 0.8477
Low expression 26 11 5 10
PTEN High expression 26 11 5 10 0.8477
Low expression 26 13 4 9
a p  2 test.
PR, partial response; SD, stable disease PD, progressive disease.
TABLE 2. Relationship between Average of Gene
Expressions and Gefitinib Effectiveness
Imaging evaluation
Gene PR (n  24) SD (n  9) PD (n  19) pa
EGFR 1.917  1.467 1.027  1.553 0.977  0.855 0.0053
PIK3CA 0.415  0.322 0.465  0.409 0.536  0.640 0.9332
PTEN 0.248  0.296 0.278  0.281 0.252  0.240 0.7415
a p  Kruskal-Wallis test.
PR, partial response; SD, stable disease PD, progressive disease.
FIGURE 1. Effect of EGFR mutations (A) and KRAS muta-
tions (B) on survival of patients who received gefitinib
treatment.
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DISCUSSION
We showed that, in addition to EGFR mutations, mu-
tations of the KRAS gene, as well as high expression of
PIK3CA and PTEN genes, had a signiﬁcant impact on the
survival of lung cancer patients after geﬁtinib treatment. We
were able to conﬁrm the recent report by Pao et al.14 that lung
adenocarcinomas with KRAS mutation are resistant to ge-
ﬁtinib treatment and to further extend their observation by
showing that patients with a KRAS mutation had a signiﬁ-
cantly poorer survival, as well as a ﬁnding in a phase III trial
of erlotinib, another EGFR-TKI (TRIBUTE).15
The role of EGFR expression in predicting geﬁtinib
treatment has been denied in earlier studies.16,17 However,
several investigators have recently reported on the impor-
tance of EGFR ampliﬁcation or overexpression. Cappuzzo et
al.18 recently reported that EGFR gene ampliﬁcation and
expression as determined by immunohistochemistry were
signiﬁcantly associated with prolonged survival. Tsao et al.19
also reported that the expression and ampliﬁcation of EGFR
was associated with an objective response or survival in a
phase III trial of erlotinib versus placebo. However, we did
not observe a signiﬁcant contribution of EGFR expression to
prolonged survival, although we used a different RT-PCR
than that used by previous investigators.
Sordella et al.20 reported that the PIK3CA-AKT or the
STAT pathway is activated by EGFR mutations, whereas the
RAS-MAPK pathway is not. In line with this observation,
phosphorylated Akt but not MAPK was reported to be sig-
niﬁcantly associated with geﬁtinib activity.11 Han et al.21 also
reported that intense nuclear staining of p-Akt (Ser473) was
associated with prolonged time to progression and overall
survival. Because PIK3CA and PTEN regulate phosphoryla-
tion of Akt, we hypothesized that alteration of these genes
might have some relevance to the response seen with geﬁtinib
treatment.
The PIK3CA gene is somatically mutated in several
types of human cancer. Although mutations were relatively
common in colorectal cancer (32%),10 breast cancer (26%–
40%),13,22 hepatocellular carcinoma (35%),13 and some ovar-
ian cancers (20%),22 it is rare in NSCLC (1%–4%).10,13
Although we detected PIK3CA mutation at a similar fre-
quency in our cohort, PIK3CA did not appear to affect
sensitivity to geﬁtinib. Interestingly, there was no mutually
exclusive relationship with EGFR mutations, as was seen in
the KRAS gene. However, we found that high expression of
PIK3CA signiﬁcantly correlated with overall survival, espe-
cially in patients with an EGFR mutation. Tumors constitu-
tively activated by an EGFR mutation and additional PI3K
overexpression might be more sensitive to geﬁtinib. The
mechanism of high PIK3CA expression might be attributable
to the ampliﬁcation of 3q23-29 where the PIK3CA gene is
located because this region is ampliﬁed in 12 of 19 NSCLC
cell lines (63%) by comparative genomic hybridization
(CGH).23
In NSCLC, although mutation or methylation of PTEN
was reported to be rare, high expression of PTEN has been
shown to be a signiﬁcantly favorable prognostic marker.24 In
vitro assay has proven that geﬁtinib-resistant cell lines have
reduced PTEN expression compared to parental PC9 cell line
that had an EGFR mutation (in-frame deletion).25 Breast
cancer cell lines lacking PTEN function have elevated Akt
activity and are resistant to ZD1839 (geﬁtinib). Reconstitu-
tion of PTEN function decreases Akt activity and can re-
establish sensitivity to ZD1839.26 In glioblastoma, PTEN was
also shown to be a key molecule in the PI3K pathway.27 We
found that PTEN expression did not correlate with the re-
sponse to geﬁtinib. The response was merely a surrogate for
the overall effect on survival. Indeed, we found that longer
survival was only seen in patients with high expression of
PTEN, even though they had EGFR mutations.
In conclusion, EGFR mutations are generally associ-
ated with a positive response to geﬁtinib treatment, as we and
others have previously reported. In patients without EGFR
FIGURE 2. Effect of expression of EGFR (A), PIK3CA (B), and
PTEN (C) gene expression status on survival of patients who
received gefitinib treatment. Cutoff values of expression
were median (i.e., 0.915 for EGFR, 0.324 for PIK3CA, and
0.152 for PTEN).
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mutations, tumors with KRAS mutations clearly identify pa-
tients who do not beneﬁt from geﬁtinib treatment. Among
patients with EGFR mutations, those with high expression of
PIK3CA and PTEN survive for a longer period. Thus, eval-
uating KRAS mutations, PIK3CA and PTEN expressions, in
addition to EGFR mutations, might help identify lung cancer
patients who are most suitable for geﬁtinib treatment.
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